Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma (replaced by TA137)
National Institute for Clinical Excellence
Record ID 32002000355
English
Authors' objectives:
To provide guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Authors' recommendations:
Guidance 1.1 The use of rituximab for third-line or subsequent-line, but not last-line, treatment of patients with recurrent or refractory Stage III or IV follicular lymphoma is not recommended.
1.2 For last-line treatment, rituximab is recommended only in the context of a prospective case series. All patients for whom alternative therapies have been exhausted (that is, those who are either chemo-resistant or chemo-intolerant) would be appropriate for inclusion in the case series on the basis that data are systematically collected to allow aggregation and analysis at a national level.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=29983
Year Published:
2002
URL for published report:
http://www.nice.org.uk/nicemedia/live/11923/39618/39618.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.